AMGN vs. TEVA: Amgen vs. Teva Pharmaceutical Stock Comparison

Company Profile

Amgen (AMGN) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while TEVA is classified in Pharmaceuticals.

Amgen (AMGN) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Amgen (AMGN) at 78.35% and Teva Pharmaceutical (TEVA) at 6.65% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Amgen (AMGN) at 24.14% converts revenue to bottom-line profit above its industry’s benchmark range, while Teva Pharmaceutical (TEVA) at 2.94% keeps roughly the typical share for its industry.

Both Amgen (AMGN) at 35.79% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Amgen (AMGN) at 9.95% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Amgen (AMGN) reports EPS growth of 88.23%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Amgen (AMGN) at 1.48 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Debt sits unusually high against shareholders’ equity for both Amgen (AMGN) at 3.76 and Teva Pharmaceutical (TEVA) at 2.13 — each debt-to-equity ratio is above its industry benchmark range.

Financial Strength Metrics

Dividends

Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a yield of 2.16%, ranking against industry peers normally.

Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a payout of 57.62%, ranking against industry peers normally.

Dividend Metrics

Valuation

Amgen (AMGN) at 26.69 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Amgen (AMGN) at 6.40 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

Teva Pharmaceutical (TEVA) at 6.23 sits near its industry’s typical P/B ratio, while Amgen (AMGN) at 17.35 prices above its benchmark range — AMGN looks rich relative to book.

Valuation Metrics